|Day Low/High||225.59 / 230.21|
|52 Wk Low/High||197.47 / 306.08|
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Traders are jockeying for position as we await the Fed, economic data and key earnings.
Senior columnist Adam Feuerstein says earnings from Dendreon and Vertex are the next big things in biotech.
Adam Feuerstein, Sr. Columnist for TheStreet, says Vertex Pharmaceuticals is the next big thing in biotech.
Here is this week's roundup of the dumbest actions on Wall Street.
The longer this action persists, the more anxious folks will be to put idle cash to work.
Evan Lazarus of T3Live review the day's market action and sets up your trading plan for the next session.
Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.
Here are a couple of window-dressing plays as we head into the end of the quarter.
Earnings season is well upon us, so better to be prepared than, well, taken by surprise.
Based on patterns of estimates revisions, these names might just generate some magic when they report.